Abstract
Immunocompromised patients have an increased risk of persistent COVID-19 disease. We report here the clinical course of two patients with hematologic malignancies hospitalized due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In both patients, viral evolution including new spike gene mutations that occurred following treatment with anti-SARS-CoV-2 antibodies preparations, including convalescent plasma and bamlanivimab. These cases demonstrate the possibility of antibody-resistant SARS-CoV-2 infections evolution in immunocompromised patients.
Keywords: COVID-19; SARS-CoV-2; Spike gene; bamlanivimab; convalescent plasma; immunocompromised.
All Keywords
【저자키워드】 COVID-19, convalescent plasma, SARS-CoV-2, bamlanivimab, spike gene, Immunocompromised, 【초록키워드】 Treatment, convalescent plasma, Evolution, coronavirus, Mutation, Hospitalized, spike, antibody, SARS-COV-2 infection, Infection, Immunocompromised patients, severe acute respiratory syndrome Coronavirus, bamlanivimab, COVID-19 disease, anti-SARS-CoV-2 antibodies, Clinical course, Viral, anti-SARS-CoV-2 antibody, spike gene, viral evolution, Patient, Immunocompromised, respiratory, convalescent, patients, Hematologic malignancy, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, increased risk, two patients, occurred, 【제목키워드】 Immunocompromised patient, COVID-19 infection, spike mutation, antibody treatment,
【저자키워드】 COVID-19, convalescent plasma, SARS-CoV-2, bamlanivimab, spike gene, Immunocompromised, 【초록키워드】 Treatment, convalescent plasma, Evolution, coronavirus, Mutation, Hospitalized, spike, antibody, SARS-COV-2 infection, Infection, Immunocompromised patients, severe acute respiratory syndrome Coronavirus, bamlanivimab, COVID-19 disease, anti-SARS-CoV-2 antibodies, Clinical course, Viral, anti-SARS-CoV-2 antibody, spike gene, viral evolution, Patient, Immunocompromised, respiratory, convalescent, patients, Hematologic malignancy, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, increased risk, two patients, occurred, 【제목키워드】 Immunocompromised patient, COVID-19 infection, spike mutation, antibody treatment,
{{{ 추상적인 }}}
면역 저하 환자는 지속적인 COVID-19 질병의 위험이 증가합니다. 중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 감염으로 입원한 혈액암 환자 2명의 임상 경과를 보고한다. 두 환자 모두에서 회복기 혈장 및 밤라니비맙을 포함한 항-SARS-CoV-2 항체 제제로 치료한 후 발생한 새로운 스파이크 유전자 돌연변이를 포함한 바이러스 진화. 이러한 사례는 면역 저하 환자에서 항체 내성 SARS-CoV-2 감염 진화의 가능성을 보여줍니다.
{{ 키워드: }} 코로나19; 사스 코로나바이러스 2; 스파이크 유전자; 밤라니비맙; 회복기 혈장; 면역 저하.